Arrowhead Pharmaceuticals (NASDAQ:ARWR) Posts Quarterly Earnings Results, Beats Expectations By $0.18 EPS

Arrowhead Pharmaceuticals (NASDAQ:ARWR) issued its quarterly earnings results on Thursday. The biotechnology company reported ($0.93) earnings per share for the quarter, beating the consensus estimate of ($1.11) by $0.18, FiscalAI reports. The company had revenue of $73.74 million during the quarter, compared to analysts’ expectations of $73.84 million. Arrowhead Pharmaceuticals had a negative return on equity of 56.92% and a negative net margin of 48.38%.The business’s quarterly revenue was down 86.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.75 earnings per share.

Here are the key takeaways from Arrowhead Pharmaceuticals’ conference call:

• REDEMPLO launch is outperforming expectations with >400 prescriptions written (~30 new scripts/week, >10% switches), accelerating refills, positive payer interactions, a U.S. WAC of $45,000/year, and regulatory approvals in Canada, China, Australia plus a CHMP positive opinion for the EU.
• Several high‑impact clinical catalysts are imminent — top‑line Q3 readouts for SHASTA‑3/4 and MUIR‑3 (plozasiran SHTG) to support an sNDA, first clinical data for ARO‑DIMER‑PA in Q3, and initial ARO‑MAPT CNS platform data end‑Q3/early‑Q4, with additional ARO‑INHBE/ARO‑ALK7 updates in H2 2026.
• Financial and business‑development moves strengthen optionality — concurrent financings ($700M convertible notes + $230M equity) plus other inflows left Arrowhead with nearly $1.8 billion in cash/investments, and the ARO‑PNPLA3 license to Madrigal provides $25M upfront and up to $975M in milestones plus royalties.
• Q2 results show a net loss of $132.7M (vs prior‑year quarter that included a one‑time Sarepta gain), operating expenses of ~ $215M and only about $1M of derived net product sales, reflecting heavy ongoing R&D and commercialization spending.

Arrowhead Pharmaceuticals Stock Down 6.7%

NASDAQ ARWR traded down $5.26 during trading hours on Friday, hitting $72.70. 2,699,845 shares of the company’s stock were exchanged, compared to its average volume of 1,838,659. The stock has a 50-day simple moving average of $64.30 and a 200 day simple moving average of $60.36. Arrowhead Pharmaceuticals has a 1-year low of $12.89 and a 1-year high of $79.48. The company has a current ratio of 3.38, a quick ratio of 3.38 and a debt-to-equity ratio of 0.29.

Insider Activity at Arrowhead Pharmaceuticals

In related news, insider James C. Hamilton sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, April 23rd. The stock was sold at an average price of $75.00, for a total transaction of $750,000.00. Following the completion of the sale, the insider owned 226,958 shares of the company’s stock, valued at $17,021,850. This trade represents a 4.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Daniel Joseph Apel sold 13,095 shares of the firm’s stock in a transaction that occurred on Wednesday, April 22nd. The stock was sold at an average price of $71.35, for a total value of $934,328.25. Following the sale, the chief financial officer directly owned 162,905 shares of the company’s stock, valued at $11,623,271.75. This represents a 7.44% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 33,095 shares of company stock valued at $2,326,228 in the last ninety days. 3.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in ARWR. Arrowstreet Capital Limited Partnership grew its stake in Arrowhead Pharmaceuticals by 3,142.5% in the third quarter. Arrowstreet Capital Limited Partnership now owns 2,081,689 shares of the biotechnology company’s stock valued at $71,797,000 after acquiring an additional 2,017,489 shares during the period. Deerfield Management Company L.P. acquired a new stake in Arrowhead Pharmaceuticals in the third quarter valued at approximately $34,249,000. Vestal Point Capital LP acquired a new stake in Arrowhead Pharmaceuticals in the fourth quarter valued at approximately $59,751,000. Balyasny Asset Management L.P. acquired a new stake in Arrowhead Pharmaceuticals in the third quarter valued at approximately $27,349,000. Finally, Price T Rowe Associates Inc. MD grew its stake in Arrowhead Pharmaceuticals by 660.9% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 838,818 shares of the biotechnology company’s stock valued at $55,690,000 after acquiring an additional 728,573 shares during the period. Institutional investors and hedge funds own 62.61% of the company’s stock.

Analyst Ratings Changes

ARWR has been the subject of several recent research reports. JPMorgan Chase & Co. initiated coverage on Arrowhead Pharmaceuticals in a research note on Friday, May 1st. They issued an “overweight” rating and a $88.00 price target for the company. Morgan Stanley raised Arrowhead Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $78.00 to $100.00 in a research note on Tuesday, April 21st. Royal Bank Of Canada increased their price target on Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the company an “outperform” rating in a research note on Friday. B. Riley Financial raised their target price on Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the stock a “buy” rating in a research note on Thursday, January 22nd. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Arrowhead Pharmaceuticals in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $84.90.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.